Diffuse Large B-Cell Lymphoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Diffuse Large B-Cell Lymphoma – Pipeline Review, H2 2016’, provides an overview of the Diffuse Large B-Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma

The report reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diffuse Large B-Cell Lymphoma therapeutics and enlists all their major and minor projects

The report assesses Diffuse Large B-Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc.

AbbVie Inc

Acetylon Pharmaceuticals, Inc.

Affimed GmbH

Amgen Inc.

Arrien Pharmaceuticals, LLC

Arvinas, Inc.

Asana BioSciences, LLC

AstraZeneca Plc

Aurigene Discovery Technologies Limited

Bayer AG

BeiGene, Ltd.

Biocon Limited

BioNTech AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cell Medica Limited

Cell>Point, L.L.C.

Cellular Biomedicine Group, Inc.

Clevexel Pharma SA

Constellation Pharmaceuticals, Inc.

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp.

Curis, Inc.

Cyclacel Pharmaceuticals, Inc.

eFFECTOR Therapeutics, Inc.

Eisai Co., Ltd.

EpiZyme, Inc.

Erytech Pharma SA

Evotec AG

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Genosco

Gilead Sciences, Inc.

GlaxoSmithKline Plc

H3 Biomedicine Inc.

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Immunovaccine, Inc.

Incyte Corporation

Inflection Biosciences Limited

Innovent Biologics, Inc.

Johnson & Johnson

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Kite Pharma Inc

Mabion SA

mAbxience S.A.

MedImmune LLC

Medivation, Inc.

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc.

Molplex Ltd.

MorphoSys AG

Neumedicines Inc.

Nimbus Therapeutics, LLC

Nordic Nanovector ASA

Novartis AG

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Philogen S.p.A.

Portola Pharmaceuticals, Inc.

RedHill Biopharma Ltd.

Respiratorius AB

Rhizen Pharmaceuticals S.A.

Sandoz International GmbH

Seattle Genetics, Inc.

Selvita S.A.

Shanghai Henlius Biotech Co., Ltd.

Sigma-Tau S.p.A.

Taiho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

TG Therapeutics, Inc.

TRACON Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Diffuse Large B-Cell Lymphoma Overview 8

Therapeutics Development 9

Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 11

Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 17

Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 18

Diffuse Large B-Cell Lymphoma - Products under Development by Companies 21

Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 31

Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 32

Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 110

Drug Profiles 126

Diffuse Large B-Cell Lymphoma - Dormant Projects 678

Diffuse Large B-Cell Lymphoma - Discontinued Products 682

Diffuse Large B-Cell Lymphoma - Product Development Milestones 684

Appendix 695

List of Tables

List of Tables

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2016 25

Number of Products under Development for Diffuse Large B-Cell Lymphoma – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Development by Companies, H2 2016 (Contd..1) 28

Number of Products under Development by Companies, H2 2016 (Contd..2) 29

Number of Products under Development by Companies, H2 2016 (Contd..3) 30

Number of Products under Development by Companies, H2 2016 (Contd..4) 31

Number of Products under Development by Companies, H2 2016 (Contd..5) 32

Number of Products under Investigation by Universities/Institutes, H2 2016 33

Comparative Analysis by Late Stage Development, H2 2016 34

Comparative Analysis by Clinical Stage Development, H2 2016 35

Comparative Analysis by Early Stage Development, H2 2016 36

Products under Development by Companies, H2 2016 37

Products under Development by Companies, H2 2016 (Contd..1) 38

Products under Development by Companies, H2 2016 (Contd..2) 39

Products under Development by Companies, H2 2016 (Contd..3) 40

Products under Development by Companies, H2 2016 (Contd..4) 41

Products under Development by Companies, H2 2016 (Contd..5) 42

Products under Development by Companies, H2 2016 (Contd..6) 43

Products under Development by Companies, H2 2016 (Contd..7) 44

Products under Development by Companies, H2 2016 (Contd..8) 45

Products under Development by Companies, H2 2016 (Contd..9) 46

Products under Investigation by Universities/Institutes, H2 2016 47

Diffuse Large B-Cell Lymphoma – Pipeline by 3SBio Inc., H2 2016 48

Diffuse Large B-Cell Lymphoma – Pipeline by AbbVie Inc, H2 2016 49

Diffuse Large B-Cell Lymphoma – Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 50

Diffuse Large B-Cell Lymphoma – Pipeline by Affimed GmbH , H2 2016 51

Diffuse Large B-Cell Lymphoma – Pipeline by Amgen Inc., H2 2016 52

Diffuse Large B-Cell Lymphoma – Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 53

Diffuse Large B-Cell Lymphoma – Pipeline by Arvinas, Inc., H2 2016 54

Diffuse Large B-Cell Lymphoma – Pipeline by Asana BioSciences, LLC, H2 2016 55

Diffuse Large B-Cell Lymphoma – Pipeline by AstraZeneca Plc, H2 2016 56

Diffuse Large B-Cell Lymphoma – Pipeline by Aurigene Discovery Technologies Limited, H2 2016 57

Diffuse Large B-Cell Lymphoma – Pipeline by Bayer AG, H2 2016 58

Diffuse Large B-Cell Lymphoma – Pipeline by BeiGene, Ltd., H2 2016 59

Diffuse Large B-Cell Lymphoma – Pipeline by Biocon Limited, H2 2016 60

Diffuse Large B-Cell Lymphoma – Pipeline by BioNTech AG, H2 2016 61

Diffuse Large B-Cell Lymphoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 62

Diffuse Large B-Cell Lymphoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 63

Diffuse Large B-Cell Lymphoma – Pipeline by Celgene Corporation, H2 2016 64

Diffuse Large B-Cell Lymphoma – Pipeline by Cell Medica Limited, H2 2016 65

Diffuse Large B-Cell Lymphoma – Pipeline by Cell>Point, L.L.C., H2 2016 66

Diffuse Large B-Cell Lymphoma – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 67

Diffuse Large B-Cell Lymphoma – Pipeline by Clevexel Pharma SA, H2 2016 68

Diffuse Large B-Cell Lymphoma – Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 69

Diffuse Large B-Cell Lymphoma – Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 70

Diffuse Large B-Cell Lymphoma – Pipeline by CTI BioPharma Corp., H2 2016 71

Diffuse Large B-Cell Lymphoma – Pipeline by Curis, Inc., H2 2016 72

Diffuse Large B-Cell Lymphoma – Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 73

Diffuse Large B-Cell Lymphoma – Pipeline by eFFECTOR Therapeutics, Inc., H2 2016 74

Diffuse Large B-Cell Lymphoma – Pipeline by Eisai Co., Ltd., H2 2016 75

Diffuse Large B-Cell Lymphoma – Pipeline by EpiZyme, Inc., H2 2016 76

Diffuse Large B-Cell Lymphoma – Pipeline by Erytech Pharma SA, H2 2016 77

Diffuse Large B-Cell Lymphoma – Pipeline by Evotec AG, H2 2016 78

Diffuse Large B-Cell Lymphoma – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 79

Diffuse Large B-Cell Lymphoma – Pipeline by Genentech, Inc., H2 2016 80

Diffuse Large B-Cell Lymphoma – Pipeline by Genosco, H2 2016 81

Diffuse Large B-Cell Lymphoma – Pipeline by Gilead Sciences, Inc., H2 2016 82

Diffuse Large B-Cell Lymphoma – Pipeline by GlaxoSmithKline Plc, H2 2016 83

Diffuse Large B-Cell Lymphoma – Pipeline by H3 Biomedicine Inc., H2 2016 84

Diffuse Large B-Cell Lymphoma – Pipeline by Hutchison MediPharma Limited, H2 2016 85

Diffuse Large B-Cell Lymphoma – Pipeline by ImmunoGen, Inc., H2 2016 86

Diffuse Large B-Cell Lymphoma – Pipeline by Immunomedics, Inc., H2 2016 87

Diffuse Large B-Cell Lymphoma – Pipeline by Immunovaccine, Inc., H2 2016 88

Diffuse Large B-Cell Lymphoma – Pipeline by Incyte Corporation, H2 2016 89

Diffuse Large B-Cell Lymphoma – Pipeline by Inflection Biosciences Limited, H2 2016 90

Diffuse Large B-Cell Lymphoma – Pipeline by Innovent Biologics, Inc., H2 2016 91

Diffuse Large B-Cell Lymphoma – Pipeline by Johnson & Johnson, H2 2016 92

Diffuse Large B-Cell Lymphoma – Pipeline by Juno Therapeutics Inc., H2 2016 93

Diffuse Large B-Cell Lymphoma – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 94

Diffuse Large B-Cell Lymphoma – Pipeline by Kite Pharma Inc, H2 2016 95

Diffuse Large B-Cell Lymphoma – Pipeline by Mabion SA, H2 2016 96

Diffuse Large B-Cell Lymphoma – Pipeline by mAbxience S.A., H2 2016 97

Diffuse Large B-Cell Lymphoma – Pipeline by MedImmune LLC, H2 2016 98

Diffuse Large B-Cell Lymphoma – Pipeline by Medivation, Inc., H2 2016 99

Diffuse Large B-Cell Lymphoma – Pipeline by Merck & Co., Inc., H2 2016 100

Diffuse Large B-Cell Lymphoma – Pipeline by Merck KGaA, H2 2016 101

Diffuse Large B-Cell Lymphoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 102

Diffuse Large B-Cell Lymphoma – Pipeline by Mirati Therapeutics Inc., H2 2016 103

Diffuse Large B-Cell Lymphoma – Pipeline by Molplex Ltd., H2 2016 104

Diffuse Large B-Cell Lymphoma – Pipeline by MorphoSys AG, H2 2016 105

Diffuse Large B-Cell Lymphoma – Pipeline by Neumedicines Inc., H2 2016 106

Diffuse Large B-Cell Lymphoma – Pipeline by Nimbus Therapeutics, LLC, H2 2016 107

Diffuse Large B-Cell Lymphoma – Pipeline by Nordic Nanovector ASA, H2 2016 108

Diffuse Large B-Cell Lymphoma – Pipeline by Novartis AG, H2 2016 109

Diffuse Large B-Cell Lymphoma – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 110

Diffuse Large B-Cell Lymphoma – Pipeline by Pfizer Inc., H2 2016 111

Diffuse Large B-Cell Lymphoma – Pipeline by Philogen S.p.A., H2 2016 112

Diffuse Large B-Cell Lymphoma – Pipeline by Portola Pharmaceuticals, Inc., H2 2016 113

Diffuse Large B-Cell Lymphoma – Pipeline by RedHill Biopharma Ltd., H2 2016 114

Diffuse Large B-Cell Lymphoma – Pipeline by Respiratorius AB, H2 2016 115

Diffuse Large B-Cell Lymphoma – Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 116

Diffuse Large B-Cell Lymphoma – Pipeline by Sandoz International GmbH, H2 2016 117

Diffuse Large B-Cell Lymphoma – Pipeline by Seattle Genetics, Inc., H2 2016 118

Diffuse Large B-Cell Lymphoma – Pipeline by Selvita S.A., H2 2016 119

Diffuse Large B-Cell Lymphoma – Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 120

Diffuse Large B-Cell Lymphoma – Pipeline by Sigma-Tau S.p.A., H2 2016 121

Diffuse Large B-Cell Lymphoma – Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 122

Diffuse Large B-Cell Lymphoma – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 123

Diffuse Large B-Cell Lymphoma – Pipeline by TG Therapeutics, Inc., H2 2016 124

Diffuse Large B-Cell Lymphoma – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 125

Assessment by Monotherapy Products, H2 2016 126

Assessment by Combination Products, H2 2016 127

Number of Products by Stage and Target, H2 2016 129

Number of Products by Stage and Mechanism of Action, H2 2016 134

Number of Products by Stage and Route of Administration, H2 2016 139

Number of Products by Stage and Molecule Type, H2 2016 141

Diffuse Large B-Cell Lymphoma – Dormant Projects, H2 2016 692

Diffuse Large B-Cell Lymphoma – Dormant Projects (Contd..1), H2 2016 693

Diffuse Large B-Cell Lymphoma – Dormant Projects (Contd..2), H2 2016 694

Diffuse Large B-Cell Lymphoma – Dormant Projects (Contd..3), H2 2016 695

Diffuse Large B-Cell Lymphoma – Discontinued Products, H2 2016 696

Diffuse Large B-Cell Lymphoma – Discontinued Products (Contd..1), H2 2016 697

List of Figures

List of Figures

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2016 25

Number of Products under Development for Diffuse Large B-Cell Lymphoma – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Investigation by Universities/Institutes, H2 2016 33

Comparative Analysis by Late Stage Development, H2 2016 34

Comparative Analysis by Clinical Stage Development, H2 2016 35

Comparative Analysis by Early Stage Products, H2 2016 36

Assessment by Monotherapy Products, H2 2016 126

Number of Products by Top 10 Targets, H2 2016 128

Number of Products by Stage and Top 10 Targets, H2 2016 128

Number of Products by Top 10 Mechanism of Actions, H2 2016 133

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 133

Number of Products by Routes of Administration, H2 2016 138

Number of Products by Stage and Routes of Administration, H2 2016 138

Number of Products by Top 10 Molecule Types, H2 2016 140

Number of Products by Stage and Top 10 Molecule Types, H2 2016 140

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared